Evidence map›Paper›PMID 38790900›Full record

ArticleBiomedicines2024

The Randomized, Multicenter, Open-Label, Controlled POLBOS 3 Trial Comparing Regular Drug-Eluting Stents and the Sirolimus-Eluting BiOSS LIM C Dedicated Coronary Bifurcation Stent: Four-Year Results.

Robert J Gil, Adam Kern, Krystian Bojko, Aneta Gziut-Rudkowska, Dobrin Vassilev, Jacek Bil

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Robert J GilDepartment of Cardiology, State Medical Institute of the Ministry of Interior and Administration, 02-507 Warsaw, Poland.ORCID 0000-0002-9041-3313
Adam KernDepartment of Cardiology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury, 10-719 Olsztyn, Poland.ORCID 0000-0003-3341-3701
Krystian BojkoDepartment of Cardiology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury, 10-719 Olsztyn, Poland.
Aneta Gziut-RudkowskaDepartment of Cardiology, State Medical Institute of the Ministry of Interior and Administration, 02-507 Warsaw, Poland.
Dobrin VassilevMedica Cor University Hospital, University of Ruse, 7017 Ruse, Bulgaria.
Jacek BilDepartment of Invasive Cardiology, Centre of Postgraduate Medical Education, 01-826 Warsaw, Poland.ORCID 0000-0002-8724-5611

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This multicenter, randomized study aimed to compare the sirolimus-eluting BiOSS LIM C dedicated coronary bifurcation stent with second-generation -limus drug-eluting stents (rDESs) in the treatment of non-left main (non-LM) coronary bifurcation. The deployment of a single stent in the main vessel-main branch across a side branch was the default strategy in all patients. The primary endpoint was the rate of major cardiovascular events (cardiac death, myocardial infarction, and target lesion revascularization) at 48 months. We enrolled 230 patients, allocating 116 patients to the BiOSS LIM C group and 114 patients to the rDES group. Most procedures were elective (BiOSS vs. rDES: 48.3% vs. 59.6%,

Indexed as

high-risk PCIlong-term datanon-LM bifurcationpercutaneous coronary intervention

Identifiers

PMID38790900
PMCPMC11118130

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.